#VisualAbstract: First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive Non-Small Cell Lung Cancer
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Tag: Pembrolizumab
The addition of neoadjuvant and adjuvant pembrolizumab to standard chemotherapy and surgery may improve outcomes in patients with early-stage non-small cell lung cancer
1. At 24 months, more participants in the pembrolizumab group were alive without an event, compared with the placebo group. ...
#VisualAbstract: Pembrolizumab plus gemcitabine and cisplatin improves survival in advanced biliary tract cancer
1. Median overall survival was greater in the pembrolizumab group compared to the control group (12.7 months vs. 10.9 months). 2. ...
Pembrolizumab plus gemcitabine and cisplatin improves survival in advanced biliary tract cancer
1. Median overall survival was greater in the pembrolizumab group compared to the control group (12.7 months vs. 10.9 months). ...
#VisualAbstract: Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma
1. Event-free survival at 2 years was longer in the neoadjuvant-adjuvant group vs the adjuvant-only group (72% vs 49%). 2. ...
Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma
1. Event-free survival at 2 years was longer in the neoadjuvant-adjuvant group vs the adjuvant-only group (72% vs 49%). 2. ...
#VisualAbstract: Adjuvant pembrolizumab improves distant metastasis-free survival in stage IIB-C melanoma
Click to read this study in The Lancet Oncology.
Adjuvant pembrolizumab improved distant-metastasis free survival and lowered risk of recurrence in melanoma patients
1. In the pembrolizumab arm, distant metastasis-free survival was significantly improved and the risk of recurrence remained lower than the ...
#VisualAbstract: Pembrolizumab provides survival benefit in PD-L1 positive advanced head and neck cancer
1. Pembrolizumab-alone or pembrolizumab-chemotherapy prolonged overall survival vs cetuximab-chemotherapy in the PD-L1 positive population 2. While pembrolizumab-chemotherapy found an improved ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
